Cancer drug with cannabishttps://nasdaqnewsreports.blogspot.ca/2018/02/pascal-biosciences-cannabis.html This article is amazing onPascal Biosciences (PAS.V). $2 target but I think it goes a lot higher. Highlights from it: 1. PAS says that they are the first company to identify a mechanism in which cannabinoids may provide a direct benefit in immunotherapy. Any company can say anything but this article writer actually did the research to confirm that's the case under the U.S. Government's cancer site. 2. PAS is actually applying for patents right now. That CEO explanation is a good one. "With respect to Composition of Matter, natural products such as cannabinoids derived from Cannabis cannot be patented; synthetic cannabinoids with novel, non-obvious structures can be patented. Our press release described the novel discovery that compounds from Cannabis can enhance the immunogenicity of tumor cells. This is a novel discovery this has never been described in the scientific literature and thus provides a patentable Method of Use for cannabinoids." 3. GWPH is a good senior comparable and possible suitor to buy out PAS, and it has a $3 billion valuation. Obviously GWPH is a lot further along. How much should PAS be valued at? Even just 5% of GWPH's value is $150 million US. We are way too low here at 45 cents Read more at https://www.stockhouse.com/companies/bullboard/c.mari/maricann-group-inc?postid=27644781#ej4ViaVEBh8wlUCj.99